phase III trial


Also found in: Dictionary, Thesaurus, Legal, Encyclopedia.

phase III trial

, phase 3 trial
A clinical trial to explore the clinical use of a new drug, esp. relative to other known effective agents (the current standard of care). These trials often include thousands of enrollee patients. By law, all such patients receive real treatment; no placebos are given. But the trial is usually double-blinded, with patients divided randomly into two groups: an experimental group and a control group on standard treatment, with neither patients nor researchers knowing to which group the patient belongs.
See also: trial
References in periodicals archive ?
Across the low, mid, and high Bio-E-Gel doses tested in the Phase III trial, there was a clear dose response in the reduction in the number and severity of hot flashes.
Bio-E-Gel Phase III trial results indicate the lowest effective dose of Bio-E-Gel thereby establishing the safest dose of Bio-E-Gel for women to reduce hot flashes.
The Dutton report states, "Based on the assumptions that Nymox will announce a marketing collaborator over the near term and will be in Phase III clinical trials next year at this time, and comparing the current value of Nymox to an average of comparable biopharmaceutical companies in Phase III trials, we arrive at our 12-month price target on the common shares of $6.
One of the reasons cited was competition within medical centers between participation in phase II versus phase III trials.
While there is some risk, dosing improvements over previous failed trials give cethromycin a good chance of yielding positive results in ongoing Phase III trials.
Two Phase III trials are enrolling to evaluate cethromycin 300 mg once-daily in CAP
Efficacy of Nebulized Arformoterol, a Long-Acting Beta2-Adrenergic Bronchodilator, in Patients with COPD: Results from Two Pooled Phase III Trials
Dziewanowska, Vice President, Clinical Research at Ligand Pharmaceuticals conducted a retrospective pooled analysis of 1,213 patients in SPIRIT I and II phase III trials to evaluate the presence of biomarker correlates of prolonged survival.
A study presented by Andres Negro-Vilar, Executive Vice President of R&D at Ligand Pharmaceuticals described the results of the analysis of lung tumor biopsies from a subset of patients in the SPIRIT I and II phase III trials.